期刊
AMERICAN JOURNAL OF CLINICAL PATHOLOGY
卷 130, 期 6, 页码 920-926出版社
OXFORD UNIV PRESS INC
DOI: 10.1309/AJCPSDG53BEANCYE
关键词
HER2; Breast; Fluorescence in situ hybridization; FISH; In situ hybridization; Amplification; Copy number; Chromosome 17; Aneusomy; Trastuzumab
类别
资金
- Roche Products, Welwyn Garden City, England
Our purpose was to determine the accuracy of diagnosis of HER2 amplification by analysis of HER2 copy number. HER2 and chromosome 17 were measured by dual-color fluorescence in situ hybridization in breast cancer samples. At a HER2 copy number of 2 to less than 3, 16 (3.3%) of 488 cases had HER2 amplification; and at a copy number of 3 to less than 4, 32 (16.4%) of 195 cases were amplified. The proportion of cases with HER2 amplification increased considerably at HER2 copy numbers of 4 to less than 7: 50.0% at 4 to less than 5: 67.5 % at 5 to less than 6, and 77.3% at 6 to less than 7. Virtually all cases were amplified at HER2 copy numbers of 7 or more. We recommend that all breast cancer cases with a HER2 copy number of 2 to 7 determined by single-color in situ hybridization should also be analyzed for chromosome 17 to obtain a more accurate diagnosis of HER2 amplification.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据